Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$6.12 -2.1%	$8.32	$2.56 ▼ $11.67	$270.75M	1.62	135,637 shs	64,765 shs
FBRX Forte Biosciences	$0.74 +2.8%	$0.71	$0.38 ▼ $1.15	$26.90M	0.48	32,489 shs	2,845 shs
GERN Geron	$3.56 -0.6%	$2.83	$1.64 ▼ $4.05	$1.95B	0.62	11.11 million shs	9.07 million shs
UMRX Cogent Biosciences	$6.54 -6.0%	$10.50	$0.29 ▼ $3.72	$277.75M	3.93	1.22 million shs	1.78 million shs
UROV Urovant Sciences	$16.24	$16.23	$7.15 ▼ $16.26	$531.75M	2.36	114,469 shs	N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	-2.08%	-8.93%	-30.85%	-21.44%	+127.51%
FBRX Forte Biosciences	+4.08%	-5.26%	+6.95%	-1.11%	-30.28%
GERN Geron	-0.56%	-4.56%	+7.88%	+64.81%	+46.50%
UMRX Cogent Biosciences	0.00%	-1.06%	+12.08%	+47.63%	-39.33%
UROV Urovant Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	1.6866 of 5 stars	3.5	3.0	0.0	0.0	0.0	3.3	0.0
FBRX Forte Biosciences	3.093 of 5 stars	3.3	4.0	0.0	0.0	2.2	2.5	1.3
GERN Geron	2.9974 of 5 stars	3.5	1.0	0.0	1.3	2.0	1.7	0.6
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	3.00	Buy	$16.50	169.61% Upside
FBRX Forte Biosciences	2.50	Moderate Buy	$2.75	272.12% Upside
GERN Geron	3.00	Buy	$5.33	49.81% Upside
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest EPIX, UMRX, GERN, FBRX, and UROV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
4/10/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
4/8/2024	FBRX Forte Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.75
3/15/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
3/15/2024	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/15/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
2/28/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
GERN Geron	$240K	8,111.91	N/A	N/A	$0.46 per share	7.74
UMRX Cogent Biosciences	$22.50M	12.34	N/A	N/A	$1.04 per share	6.29
UROV Urovant Sciences	N/A	N/A	N/A	N/A	($1.90) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
FBRX Forte Biosciences	-$31.48M	-$1.04	N/A	N/A	N/A	N/A	-94.27%	-81.36%	5/20/2024 (Estimated)
GERN Geron	-$184.13M	-$0.33	N/A	N/A	N/A	-77,691.14%	-63.33%	-44.71%	5/9/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A
UROV Urovant Sciences	-$146.74M	-$4.71	N/A	N/A	N/A	N/A	N/A	-162.90%	N/A

Latest EPIX, UMRX, GERN, FBRX, and UROV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2024	Q4 2023	FBRX Forte Biosciences	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A
2/28/2024	Q4 23	GERN Geron	-$0.10	-$0.09	+$0.01	-$0.09	$0.06 million	$0.02 million
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
UROV Urovant Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	40.74	40.74
FBRX Forte Biosciences	N/A	10.45	10.45
GERN Geron	0.14	3.16	3.16
UMRX Cogent Biosciences	0.18	2.90	2.90
UROV Urovant Sciences	N/A	2.91	2.91

Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
FBRX Forte Biosciences	77.63%
GERN Geron	73.71%
UMRX Cogent Biosciences	26.39%
UROV Urovant Sciences	18.44%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	14.70%
FBRX Forte Biosciences	10.53%
GERN Geron	3.10%
UMRX Cogent Biosciences	31.50%
UROV Urovant Sciences	2.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
FBRX Forte Biosciences	9	36.40 million	32.56 million	Optionable
GERN Geron	141	546.87 million	529.92 million	Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable
UROV Urovant Sciences	70	32.74 million	N/A	Not Optionable

EPIX, UMRX, GERN, FBRX, and UROV Headlines

Source	Headline
	OC Drugmakers Cut Headcounts, Close Offices ocbj.com - April 22 at 7:23 PM
	A2 Bio’s new CEO aims to grow platform pacbiztimes.com - April 8 at 6:15 AM
	C-Suite Shuffle: A2 Bio, Bayer, BioNTech and More biospace.com - March 27 at 2:46 AM
	A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors finance.yahoo.com - March 26 at 3:06 AM
	HEALTH BEHAVIOR AND NUTRITION SCIENCES udel.edu - February 17 at 2:30 PM
	Bulletin Science and Security Board thebulletin.org - February 15 at 3:32 PM
	Secretary-General’s Guidance Note on Behavioural Science un.org - February 5 at 9:35 AM
	Marine Sciences & Technology uml.edu - January 7 at 12:52 PM
	The 7 Best Science Kits for Kids and Teens popularmechanics.com - December 22 at 12:32 AM
	Careers in Computer Science mccormick.northwestern.edu - December 11 at 10:18 AM
	PhD in Information Science drexel.edu - December 8 at 10:01 AM
	Petauri™ Elects William Fleming and James Robinson to Its Board of Directors finance.yahoo.com - December 6 at 10:09 AM
	Core Requirements & Courses bc.edu - December 1 at 1:25 PM
	Inspiring Women in Science nature.com - November 28 at 10:11 AM
	Develop your own cognitive toolkit. miamioh.edu - November 17 at 9:55 AM
	Benign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsight medgadget.com - November 16 at 8:17 AM
	PM360 Announces 2023 Trailblazer Award Winners finance.yahoo.com - October 4 at 8:59 AM
	Heavy Drinking Not Tied to Lower Response to DAAs for Hepatitis C medpagetoday.com - September 26 at 3:23 PM
	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors finance.yahoo.com - September 11 at 8:30 AM
	Clinical and Translational Science Institute buffalo.edu - September 8 at 9:36 PM
	MDxHealth CEO Bullish After Q2 Revenue Boost ocbj.com - September 5 at 8:49 PM
	Windmill Model Science Project education.com - August 15 at 1:51 AM
	Top Science News sciencedaily.com - August 10 at 1:52 PM
	About This Site sciencedaily.com - August 5 at 4:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Forte Biosciences

NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Geron

NASDAQ:GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Urovant Sciences

NASDAQ:UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial